BIO:ON Insight #12 · Aug 18, 2026
The week a drug learned to erase proteins, a recall came down to a shard of glass
BMS wins the world's first molecular glue approval, ex-Pfizer chemists raise $95M to turn injections into pills, and a biosimilar batch is recalled over glass particles. The week a drug learned to erase proteins, a recall came down to a shard of glass.
What I learned this week
If there's one line for this week, it's this: a drug is never finished by its molecule alone. A world-first approval and a glass-particle recall landing in the same week looks like coincidence, but they're really telling the same story: the most glamorous step and the most boring-looking one matter just as much. Next time you see "breakthrough," ask which gate it's actually about. See you next issue. 🙏
Yaehyun Lee · Quoted from the Editor's Insight I wrote for this issue.
Stories in this issue
- FDA Approvals
BMS's Zenbexus: first CELMoD protein degrader approved by the FDA
Bristol Myers SquibbZenbexusUS FDA
- Pipeline Analysis
Khartis Therapeutics raises a $95M Series A
Khartis Therapeutics
- Market Trends
Fresenius Kabi recalls Tyenne over glass particles
Fresenius KabiTyenne
AI summary
- 1BMS won the world's first FDA approval for a molecular glue protein degrader.
- 2Former Pfizer chemists launched a biotech with $95M to turn injectables into pills.
- 3Fresenius recalled an arthritis biosimilar over glass particles.
Relevant rolesCMC & QAR&DRegulatory affairs
Summary and tags generated by AI from the issue text.
References
- 1.BMS Zenbexus — world's first CELMoD targeted protein degrader approved by FDA (opens in a new tab)
Fierce Pharma, Aug 14, 2026
- 2.Khartis Therapeutics — $95M Series A to turn injections into pills (opens in a new tab)
Fierce Biotech, Aug 13, 2026
- 3.Fresenius Kabi recalls Tyenne biosimilar batch over glass particles (opens in a new tab)
Fierce Pharma, Aug 12, 2026
Related insights
Other issues covering the same companies, drugs or topics